

Dengue Drug Discovery Portfolio at NITD

Viral targets

NS5 RNA-dependent RNA polymerase (NTU)

- Nucleoside inhibitor
- Prodrug of nucleoside inhibitor
- Non-nucleoside inhibitor

NS5 methyltransferase (NTU, SIB, SLLC, UB, WC)

Host targets

Cholesterol biosynthesis (NIBR)

Cell-based approach

High throughput screening for anti-dengue activity in cell-based assays has been completed and is being followed by target deconvolution and lead identification (GNF, NIBR)

Virus-like particles (VLP)

Therapeutic antibodies:

In collaboration with ETC and NUS.

Abbreviations:

- NIBR: Novartis Institutes for Biomedical Research
- GNF: Genomics Institute of the Novartis Foundation
- NTU: Nanyang Technological University
- NUS: National University Singapore
- ETC: Experimental Therapeutics Centre, A*STAR
- SIB: Swiss Institute of Bioinformatics
- SLLC: Schrödinger LLC
- UB: University of Bristol
- WC: Wadsworth Center